Ocrevus FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
Ocrevus (ocrelizumab) is a humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal nerve cell damage. Ocrevus is indicated as a treatment for both relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis.
Development timeline for Ocrevus
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.